1. IndiaInfoline
  2. Search
Displaying Results for "lupin"
Showing Results 1 - 19 of 1721

Lupin bounces back, up 1.4%

India Infoline News Service  | Mumbai February 26, 2015 10:46 IST

The stock has gained 2.7 per cent in intra-day deals on tie-up with Acceliant.

Lupin stock ends 3% lower

India Infoline News Service  | Mumbai February 23, 2015 16:48 IST

The stock hit an intra-day high of Rs. 1,703 and a low of Rs. 1,604 on BSE, while the total traded quantity on the counter stood at over 1.32 lk shares

Lupin drops as FDA raises concerns over Pithambur facility

capital market  | Mumbai February 23, 2015 15:15 IST

Lupin fell 2.49% to Rs 1648.80 at 15:21 IST on BSE after the company said that US Food & Drug Administration inspected the company's Pithambur plant in January this year, after which it issued the company a Form 483, listing six observations.

Lupin gets US FDA approval for Generic Lumigan Ophthalmic Solution 0.03%

India Infoline News Service  | Mumbai February 23, 2015 14:16 IST

Lupin's Bimatoprost Ophthalmic Solution, 0.03% filing was made from its Indore facility which was audited in January, 2015.

Lupin gets approval to market Bimatroprost Ophthalmic Solution, 0.03%

capital market  | Mumbai February 23, 2015 13:50 IST

From USFDA

Lupin stock down 3%

India Infoline News Service  | Mumbai February 23, 2015 11:18 IST

The stock has hit a high of Rs. 1703 and a low of Rs. 1604.

Lupin gets approval to market Bimatroprost Ophthalmic Solution, 0.03%

capital market  | Mumbai February 23, 2015 00:00 IST

Lupin announced that it has received final approval for its Bimatroprost Ophthalmic Solution, 0.03% from the United States Food & Drug Administration (FDA) to market a generic version of Allergen Inc.'s Lumigan Ophthalmic Solution 0.03%.

Lupin Limited - Press Release

capital market  | Mumbai February 23, 2015 00:00 IST

Lupin Limited has informed the Exchange regarding a press release dated February 23, 2015, titled Lupin Receives US FDA Approval for Generic Lumigan Ophthalmic Solution 0.03%.

Lupin stock up 1%

India Infoline News Service  | Mumbai February 19, 2015 10:24 IST

The stock has registered a fresh all-time high at Rs. 1,706 this morning.

Lupin scales record high on launching InspiraChamber in US

capital market  | Mumbai February 19, 2015 09:55 IST

Lupin rose 0.86% to Rs 1,695.95 at 09:48 IST on BSE after the company's US subsidiary launched the all new InspiraChamber Anti-Static Valved Holding Chamber in the United States.

Lupin launches InspiraChamber Anti-Static Valved Holding Chamber (VHC)

capital market  | Mumbai February 18, 2015 17:58 IST

In United States

Lupin launches InspiraChamber Anti-Static VHC in US

India Infoline News Service  | Mumbai February 18, 2015 15:51 IST

The agreement grants Lupin exclusive rights to promote, distribute and market InspiraChamber VHC in the United States.

Lupin and Celon announce Strategic Development and Licensing agreement for Generic Advair Diskus

India Infoline News Service  | Mumbai February 18, 2015 15:38 IST

This collaboration is an important milestone in Lupin's efforts to evolve its global inhalation pipeline, Vinita Gupta said.

Lupin allots equity shares

capital market  | Mumbai February 18, 2015 14:57 IST

Under ESOP

Lupin gains on announcing agreement for Generic Advair Diskus

capital market  | Mumbai February 18, 2015 09:23 IST

Lupin rose 1.21% to Rs 1,679 at 09:21 IST on BSE after the company entered into a definitive agreement with Celon to jointly develop a fluticasone/salmeterol dry powder inhaler product.

Lupin Limited - Press Release

capital market  | Mumbai February 18, 2015 00:00 IST

Lupin Limited has informed the Exchange regarding press release dated February 18, 2015 titled Lupin Launches InspiraChamber Anti-Static Valved Holding Chamber (VHC) in the US Expands US Brands Portfolio.

Lupin allots equity shares

capital market  | Mumbai February 18, 2015 00:00 IST

Lupin announced that the Allotment Committee of Directors at its meeting held on 18 January 2015 has allotted 27951 fully paid up equity shares of Rs. 2/- each. These shares have been allotted upon exercising of options granted to the employees under Stock option plans of the Company.<p>In view of the above, the issued and paid up capital of the Company has been increased to Rs. 89,87,19,508 consisting 44,93,59,754 equity shares of Rs. 2/- each.

Lupin & Celon to jointly develop inhalation product

capital market  | Mumbai February 17, 2015 15:54 IST

A generic version of GlaxoSmithKline's Advair Diskus

Lupin & Celon to jointly develop inhalation product

capital market  | Mumbai February 17, 2015 00:00 IST

Lupin and Celon Pharma S.A. (Celon) announced that they have entered into a definitive agreement under which the companies will jointly develop fluticasone / salmeterol dry powder inhaler (DPI) product which is a generic version of GlaxoSmithKline's Advair Diskus. Lupin will be responsible for commercialization of the product. Celon will supply the product to Lupin for its commercialization in the United States, Canada, Mexico and other key markets.

Back to Top

Reports
News